Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 1/20 | 0.44 |
| ▸ | ICMT | O60725 | 2/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | ALB | P02768 | 1/20 | 0.43 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | SOAT2 | O75908 | 1/20 | 0.40 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17022605 | 1.00 | SRC (0.44) | SRCICMTCNR2ALBPLA2G2A | |
| SCHEMBL17022517 | 0.89 | CNR1 (0.44) | CNR2MAPTMEN1HTTKMT2A | |
| SCHEMBL17022708 | 0.88 | GSK3B (0.45) | SRCMAPTSOAT2SOAT1MEN1 | |
| SCHEMBL17022581 | 0.88 | PLA2G2A (0.48) | ICMTCNR2ALBPLA2G2A | |
| SCHEMBL17022566 | 0.88 | SRC (0.43) | SRCICMTCNR2ALBMEN1 | |
| SCHEMBL17022496 | 0.80 | PLA2G2A (0.46) | CNR2PLA2G2AMAPTMEN1ALDH1A1 | |
| SCHEMBL17022660 | 0.79 | SRC (0.40) | SRCCNR2MAPTMEN1KMT2A | |
| SCHEMBL17022595 | 0.78 | CNR1 (0.47) | CNR2PLA2G2AMAPTMEN1ALDH1A1 | |
| SCHEMBL17022584 | 0.78 | MEN1 (0.39) | CNR2MEN1KMT2A | |
| SCHEMBL17022590 | 0.78 | PLA2G2A (0.40) | PLA2G2AMEN1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2910547-B1 | COMPOUND; TAUTOMER AND GEOMETRIC ISOMER THEREOF; SALT OF SAID COMPOUND, TAUTOMER, OR GEOMETRIC ISOMER; METHOD FOR MANUFACTURING SAID COMPOUND, TAUTOMER, ISOMER, OR SALT; ANTIMICROBIAL AGENT; AND ANTI-INFECTIVE DRUG | UNIV OKAYAMA (JP) | 2017-06-14 | — | — | EP | disclosed |
| US-9512075-B2 | Compound; tautomer and geometric isomer thereof; salt of said compound, tautomer, or geometric isomer; method for manufacturing said compound, tautomer, isomer, or salt; antimicrobial agent; and anti-infective drug | OKAYAMA UNIVERSITY (JP) | 2016-12-06 | — | — | US | disclosed |
| US-20150291523-A1 | COMPOUND; TAUTOMER AND GEOMETRIC ISOMER THEREOF; SALT OF SAID COMPOUND, TAUTOMER, OR GEOMETRIC ISOMER; METHOD FOR MANUFACTURING SAID COMPOUND, TAUTOMER, ISOMER, OR SALT; ANTIMICROBIAL AGENT; AND ANTI-INFECTIVE DRUG | MICROBIAL CHEMISTRY RESEARCH FOUNDATION (JP) | 2015-10-15 | — | — | US | disclosed |
| EP-2910547-A1 | COMPOUND; TAUTOMER AND GEOMETRIC ISOMER THEREOF; SALT OF SAID COMPOUND, TAUTOMER, OR GEOMETRIC ISOMER; METHOD FOR MANUFACTURING SAID COMPOUND, TAUTOMER, ISOMER, OR SALT; ANTIMICROBIAL AGENT; AND ANTI-INFECTIVE DRUG | Okayama University (JP) | 2015-08-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150291523-A1 | COMPOUND; TAUTOMER AND GEOMETRIC ISOMER THEREOF; SALT OF SAID COMPOUND, TAUTOMER, OR GEOMETRIC ISOMER; METHOD FOR MANUFACTURING SAID COMPOUND, TAUTOMER, ISOMER, OR SALT; ANTIMICROBIAL AGENT; AND ANTI-INFECTIVE DRUG | FURIN, ACE, SHARPIN | SRC 2158/4885ICMT 135/4885CNR2 4572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.